No Data
Shenzhen Lifotronic Technology Gets Medical Device Registration for Spectral Therapeutic Device; Shares Down 7%
Shenzhen Lifotronic Technology Co., Ltd. (688389.SH): The international market is expected to have higher expectations for mid-speed luminometers.
On November 8, Golon Hui learned that Shenzhen Lifotronic Technology Co., Ltd. (688389.SH) stated during a specific target survey that the company's large light products are mainly promoted to public hospitals in the international market. The market characteristics of different countries vary. In some countries, laboratories are government-led in procurement and tend to prefer large equipment, while medical institutions in some countries tend to choose medium-speed models. For most countries, due to population constraints, there is not a high demand for large light and assembly line products. Medium-speed light instruments can meet the tender requirements of many public hospitals in overseas countries, which the company's research and development of medium-speed light instruments can expand the market for small light instruments.
shenzhen lifotronic technology co., ltd. (688389): Steady growth in performance, advancing the installation of light emitting production lines.
Investment Highlights: Event: The company released the third quarter report of 2024, with revenue of 0.267 billion in the third quarter of 2024 (+6.4%), net income attributable to the parent company of 85.54 million (+21.51%), and non-net income attributable to the parent company of 80 million.
shenzhen lifotronic technology co., ltd. (688389) Third Quarter Report Review in 2024: IVD continues to grow rapidly, stock-based incentives demonstrate long-term confidence.
Performance Summary: In the first three quarters of 2024, the company achieved revenue of 0.857 billion, +5.89% year-on-year, net income attributable to the parent company was 0.257 billion, +25.62%, and in single quarter 3, revenue was 0.267 billion, +6.45%, net income attributable to the parent.
Shenzhen Lifotronic Technology Co., Ltd. (688389): Adhering to technology orientation, Q3 R&D expense ratio increased.
Event: The company released the third quarter report for 2024. In 3Q2024, the revenue was 0.267 billion yuan, up 6.45% year-on-year; the net income attributable to the parent company was 0.086 billion yuan, up 21.51% year-on-year; and the non-net income attributable to the parent company is 0.
Pumen Technology: Shenzhen Pumen Technology Co., Ltd. 2024 Third Quarter Report
No Data
No Data